Pediatric acute lymphoblastic leukemia (ALL) is a cancer of the bone marrow in which immature white blood cells called lymphoblasts multiply out of control and crowd out normal blood production. It is the most common cancer of childhood, it usually shows up as tiredness, pallor, bruising, fever, or bone pain, and with modern treatment the large majority of children are cured.
As a hematologist, I find that parents facing this diagnosis want two things quickly: a clear picture of what is happening inside their child’s body, and an honest sense of what the next two to three years will look like. This guide covers both, from the first symptoms to the end of maintenance therapy.
What Is Pediatric Acute Lymphoblastic Leukemia?
Acute lymphoblastic leukemia is a hematologic malignancy. It begins in the bone marrow, the spongy tissue inside bones where blood cells are made. Normally, early lymphoid cells mature into B and T lymphocytes that fight infection. In ALL, one of these early cells acquires genetic changes that freeze it in an immature state and let it divide endlessly.
The word acute means the disease develops over weeks rather than years, and without treatment it progresses rapidly. The word lymphoblastic tells us which cell line is involved. Most childhood cases arise from B-cell precursors (B-ALL), while a smaller share arise from T-cell precursors (T-ALL).
ALL is the most common form of childhood leukemia, accounting for roughly three out of four leukemia cases in children and about a quarter of all childhood cancers. It peaks between the ages of 2 and 5. If you want to see how it compares with acute myeloid leukemia and the rarer childhood forms, see our overview of the different types of childhood leukemia. Our leukemia guide covers the adult forms as well.
Causes and Risk Factors
For most children, there is no identifiable cause, and nothing the parents did or failed to do led to the illness. That point matters, because guilt is one of the first emotions many families describe. ALL arises from a series of acquired genetic changes in a single developing blood cell, some of which may be present from before birth.
Recognized risk factors include:
- Inherited genetic conditions, particularly Down syndrome, which carries a considerably higher risk of ALL, as well as rarer syndromes such as Li-Fraumeni and ataxia-telangiectasia.
- Acquired chromosomal changes in the leukemic cells, such as the ETV6-RUNX1 fusion (also called TEL-AML1) or extra copies of chromosomes (hyperdiploidy).
- High-dose ionizing radiation, including significant exposure before birth.
- Prior chemotherapy for another cancer, which is uncommon in children.
- Having an identical twin with ALL, especially when diagnosed in infancy.
Researchers have also identified changes in genes such as IKZF1 and PAX5 that disrupt normal lymphoid development. These findings mostly help with risk grouping rather than prevention, since ALL cannot currently be prevented.
Signs and Symptoms Parents Notice
The symptoms of ALL come from two processes: the marrow failing to make normal blood cells, and leukemic cells spreading to other organs. Early signs are often vague and easily mistaken for a viral illness, which is why a persistent pattern matters more than any single symptom.
| Underlying problem | What you may see |
|---|---|
| Low red cells (anemia) | Pale skin, tiredness, shortness of breath with play, irritability |
| Low platelets (thrombocytopenia) | Easy bruising, tiny red-purple spots (petechiae), nosebleeds, gum bleeding |
| Too few healthy white cells | Fevers, infections that linger or keep returning |
| Marrow crowded by blasts | Bone or joint pain, limping, refusing to walk |
| Leukemic cells in organs | Swollen glands, enlarged liver or spleen (swollen belly), rarely headache or breathing difficulty from a chest mass in T-ALL |
Bone pain deserves special mention. Young children with ALL are sometimes first assessed for arthritis or a sports injury, because a limp or night-time leg pain can be the most striking complaint.
How Pediatric ALL Is Diagnosed
Diagnosis usually starts with a complete blood count (CBC) and a blood smear. Typical findings are anemia, a low platelet count, and a white cell count that may be low, normal, or very high, often with blasts visible on the smear. A normal white count does not rule leukemia out.
The definitive test is a bone marrow aspiration and biopsy, usually done under sedation in children. A diagnosis of ALL requires at least 20% lymphoblasts in the marrow, and in practice the marrow is often almost completely replaced by blasts. For background on what healthy marrow looks like, see our article on the composition and function of bone marrow.
Further tests on the marrow sample include:
- Flow cytometry (immunophenotyping): identifies surface markers. B-ALL typically expresses CD19, CD10, CD22, and TdT; T-ALL expresses CD7 and cytoplasmic CD3.
- Cytogenetics and molecular testing: look for chromosome changes that shape risk and treatment, such as hyperdiploidy, ETV6-RUNX1, KMT2A rearrangements, or the Philadelphia chromosome.
- Lumbar puncture: checks the spinal fluid for leukemic cells, because the central nervous system is a common hiding place.
Treatment Phases and What to Expect
Treatment for pediatric ALL is mainly chemotherapy, delivered in phases over roughly two to three years. The intensity is tailored to each child’s risk group, which is based on age, white count at diagnosis, genetic features, and, most importantly, how quickly the leukemia responds.
| Phase | Typical length | Goal |
|---|---|---|
| Induction | About 4 weeks | Clear visible leukemia and achieve remission |
| Consolidation / intensification | Several months | Destroy remaining leukemic cells, including in the central nervous system |
| Maintenance | Around 2 years or more | Prevent relapse with lower-intensity, largely oral therapy |
Induction typically combines a corticosteroid, vincristine, and asparaginase, with an anthracycline added for higher-risk patients. Intrathecal chemotherapy, given directly into the spinal fluid, is used throughout to protect the brain and spinal cord.
At the end of induction, doctors measure minimal residual disease (MRD), the tiny number of leukemic cells too few to see under a microscope. MRD is one of the strongest predictors of outcome and is used to intensify or de-escalate treatment. Stem cell transplantation is reserved for a small group of children with very high-risk or relapsed disease.
Newer Therapies and Outlook
Immunotherapy has changed the options for children whose leukemia is resistant or returns. Blinatumomab is an antibody that links T cells to CD19 on leukemic cells, and inotuzumab ozogamicin delivers a toxin to cells carrying CD22. CAR-T cell therapy reprograms a child’s own T cells to recognize and kill B-ALL cells. Children with Philadelphia-positive ALL also receive a tyrosine kinase inhibitor alongside chemotherapy.
The overall outlook is one of the great successes of pediatric oncology. In high-income settings, around 90% of children with ALL are now long-term survivors, and many risk groups do even better. Long-term follow-up after treatment watches for late effects on growth, heart, bones, fertility, and learning.
When to See a Doctor
Most bruises, fevers, and leg pains in children are harmless. Ask your pediatrician for a blood count if your child has several of the following together, or if a symptom lingers beyond a couple of weeks:
- Unusual paleness or tiredness that does not improve with rest
- Bruises in unusual places, petechiae, or frequent nosebleeds
- Fevers or infections without a clear cause
- Bone pain, limping, or waking at night with leg pain
- Swollen glands, a swollen abdomen, or unexplained weight loss
Seek urgent care for breathing difficulty, heavy bleeding, confusion, or a fever in a child already known to have low blood counts. Our guide to hematology and blood health explains the blood tests involved.
Frequently Asked Questions
Is pediatric acute lymphoblastic leukemia curable?
Yes, in most cases. The majority of children treated on modern protocols are cured and go on to live full adult lives. Outlook depends on age, genetic subtype, and especially how quickly the leukemia responds to induction.
How long does treatment for childhood ALL last?
Total treatment usually lasts about two to three years. The first six to nine months are the most intensive and involve frequent hospital visits, while maintenance is mostly oral medication at home with regular clinic checks.
Can children go to school during treatment?
Many children return to school during maintenance, and some attend part-time earlier. Your care team will advise on timing based on blood counts and infection risk, and on precautions such as avoiding contact with chickenpox or measles.
Is ALL inherited or contagious?
ALL is not contagious, and in most children it is not inherited. Siblings generally have only a slightly higher risk than other children, with identical twins the main exception.
